NEW YORK, Oct. 4, 2017 /PRNewswire/ -- The Global Gene Therapy Partnering Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
Read the full report: https://www.reportlinker.com/p03605498Trends in gene therapy partnering dealsDisclosed headlines, upfronts, milestones and royalties by stage of developmentGene therapypartnering contract documentsTop gene therapy deals
by valueThe Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How aresalesand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.Chapter 3 provides a review of the leading Gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Chapter 7 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2010.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.Report scopeGlobal Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.Global Gene Therapy Partnering Terms and Agreements includes:Trends in gene therapy dealmaking in the biopharma industry since 2010Analysis of gene therapy deal structureAccess to headline, upfront, milestone and royalty dataCase studies of real-life gene therapy dealsAccess to over 200 gene therapy dealsThe leading gene therapy deals by value since 2010Most active gene therapy dealmakers since 2010The leading gene therapy partnering resourcesIn Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:Company A-ZHeadline valueStage of development at signingDeal component typeSpecific therapy and technology targetEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Read the full report: https://www.reportlinker.com/p03605498 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/global-gene-therapy-partnering-terms-and-agreements-2010-to-2017-300531276.html